| Ytd | -41.04% | |
| 1y | -32.45% |
| Open | 2.05 | Prev Close | 2.10 | Low | 2.00 | High | 2.07 | Mkt Cap | 42.91M |
| Vol | 52.59K | Avg Vol | 171.87K | EPS | -1.17 | P/E | N/A | Forward P/E | -2.90 |
| Beta | 0.33 | Short Ratio | 3.25 | Inst. Own | 21.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 06-20 | 50-d Avg | 2.13 | 200-d Avg | 2.95 | 1yr Est | 10.44 |
GRCE News
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the ana
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Cli
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analy
TD Cowen analyst Stacy Ku maintains Grace Therapeutics (NASDAQ:GRCE) with a Buy and lowers the pr
Grace Therapeutics stock drops after FDA flags NDA issues for GTx-104; CMC concerns weigh despite no
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, an
The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analy
Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analy